Last reviewed · How we verify
Sustained Release Morphine Sulfate
Sustained Release Morphine Sulfate is a Opioid analgesic Small molecule drug developed by Labtec GmbH. It is currently FDA-approved for Moderate to severe chronic pain requiring continuous opioid therapy, Cancer pain.
Sustained-release morphine sulfate binds to opioid receptors in the central nervous system to provide prolonged pain relief.
Sustained Release Morphine Sulfate is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist drug class. It is indicated for various conditions including cancer pain, chronic pain, and opioid-induced constipation, among others.
At a glance
| Generic name | Sustained Release Morphine Sulfate |
|---|---|
| Sponsor | Labtec GmbH |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Morphine is a mu-opioid receptor agonist that modulates pain perception and emotional response to pain by acting on opioid receptors throughout the brain and spinal cord. The sustained-release formulation provides extended drug delivery over 12-24 hours, maintaining therapeutic levels and reducing dosing frequency compared to immediate-release formulations. This allows for more consistent analgesia in chronic pain management.
Approved indications
- Moderate to severe chronic pain requiring continuous opioid therapy
- Cancer pain
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Vomiting
- Respiratory depression
- Dependence/tolerance
Key clinical trials
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain (PHASE2)
- IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration (PHASE3)
- Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain (PHASE4)
- Comparison of Short-term Sustained-release Opioid in Open Abdominal Urologic Surgeries (NA)
- Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration (PHASE2)
- Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer (NA)
- Analgesic Efficacy of Sacral Neuromodulation for Pelvic Cancer Pain: A Preliminary Report (NA)
- Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sustained Release Morphine Sulfate CI brief — competitive landscape report
- Sustained Release Morphine Sulfate updates RSS · CI watch RSS
- Labtec GmbH portfolio CI
Frequently asked questions about Sustained Release Morphine Sulfate
What is Sustained Release Morphine Sulfate?
How does Sustained Release Morphine Sulfate work?
What is Sustained Release Morphine Sulfate used for?
Who makes Sustained Release Morphine Sulfate?
What drug class is Sustained Release Morphine Sulfate in?
What development phase is Sustained Release Morphine Sulfate in?
What are the side effects of Sustained Release Morphine Sulfate?
What does Sustained Release Morphine Sulfate target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: Labtec GmbH — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe chronic pain requiring continuous opioid therapy
- Indication: Drugs for Cancer pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing